Target and tissue selectivity of PROTAC degraders
The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle challenging protein targets deemed undruggable with traditional small molecule inhibitors. Many promising campaigns to inhibit proteins have failed due to factors surrounding inhibition selectivity and targeting of compounds to specific tissues and cell types. One of the major improvements that PROTAC (proteolysis targeting chimera) and molecular glue technology can exert is highly selective control of target inhibition. Multiple studies have shown that PROTACs can gain selectivity for their protein targets beyond that of their parent ligands via optimization of linker length and stabilization of ternary complexes. Due to the bifunctional nature of PROTACs, the tissue selective nature of E3 ligases can be exploited to uncover novel targeting mechanisms. In this review, we provide critical analysis of the recent progress towards making selective PROTAC molecules and new PROTAC technologies that will continue to push the boundaries of achieving selectivity. These efforts have wide implications in the future of treating disease as they will broaden the possible targets that can be addressed by small molecules, like undruggable proteins or broadly active targets that would benefit from degradation in specific tissue types.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, PROTAC technology leverages E3 ligases, which may be selectively expressed in certain tissues, to drive the targeted degradation of specific targets,520 offering significant opportunities for AD treatment.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [520]
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy
Klán, P., Šolomek, T., Bochet, C. G., Blanc, A., Givens, R., Rubina, M., Popik, V., Kostikov, A., & Wirz, J. (2013) · Chemical Reviews · doi:10.1021/cr300177k · Cited by 1,827
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors
Koo, B.-K., Spit, M., Jordens, I., Low, T. Y., Stange, D. E., van de Wetering, M., van Es, J. H., Mohammed, S., Heck, A. J. R., Maurice, M. M., et al. (2012) · Nature · doi:10.1038/nature11308 · Cited by 980
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923
A deep proteome and transcriptome abundance atlas of 29 healthy human tissues
Wang, D., Eraslan, B., Wieland, T., Hallström, B., Hopf, T., Zolg, D. P., Zecha, J., Asplund, A., Li, L., Meng, C., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188503 · Cited by 750
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
Plasticity in binding confers selectivity in ligand-induced protein degradation
Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2538 · Cited by 552
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487
MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases
Doyle, J. M., Gao, J., Wang, J., Yang, M., & Potts, P. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.029 · Cited by 467
Self-citationA Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Spradlin, J. N., Hu, X., Ward, C. C., Brittain, S. M., Jones, M. D., Ou, L., To, M., Proudfoot, A., Ornelas, E., Woldegiorgis, M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0304-8 · Cited by 432
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413
Buhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394
Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase
Pineda, C. T., Ramanathan, S., Fon Tacer, K., Weon, J. L., Potts, M. B., Ou, Y.-H., White, M. A., & Potts, P. R. (2015) · Cell · doi:10.1016/j.cell.2015.01.034 · Cited by 389
Self-citationDynamics of Cullin-RING Ubiquitin Ligase Network Revealed by Systematic Quantitative Proteomics
Bennett, E. J., Rush, J., Gygi, S. P., & Harper, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.11.017 · Cited by 386
SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate
Roy, M. J., Winkler, S., Hughes, S. J., Whitworth, C., Galant, M., Farnaby, W., Rumpel, K., & Ciulli, A. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00092 · Cited by 386
Light-Induced Protein Degradation with Photocaged PROTACs
Xue, G., Wang, K., Zhou, D., Zhong, H., & Pan, Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06422 · Cited by 377
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Donovan, K. A., Ferguson, F. M., Bushman, J. W., Eleuteri, N. A., Bhunia, D., Ryu, S., Tan, L., Shi, K., Yue, H., Liu, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.038 · Cited by 359
Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
Maneiro, M., Forte, N., Shchepinova, M. M., Kounde, C. S., Chudasama, V., Baker, J. R., & Tate, E. W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00285 · Cited by 350
PHOTACs enable optical control of protein degradation
Reynders, M., Matsuura, B. S., Bérouti, M., Simoneschi, D., Marzio, A., Pagano, M., & Trauner, D. (2020) · Science Advances · doi:10.1126/sciadv.aay5064 · Cited by 321
The MAGE proteins: Emerging roles in cell cycle progression, apoptosis, and neurogenetic disease
Barker, P. A., & Salehi, A. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10160 · Cited by 320
Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
Pfaff, P., Samarasinghe, K. T. G., Crews, C. M., & Carreira, E. M. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00713 · Cited by 301
Sun, Y., Zhao, X., Ding, N., Gao, H., Wu, Y., Yang, Y., Zhao, M., Hwang, J., Song, Y., Liu, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0055-1 · Cited by 295
Light-induced control of protein destruction by opto-PROTAC
Liu, J., Chen, H., Ma, L., He, Z., Wang, D., Liu, Y., Lin, Q., Zhang, T., Gray, N., Kaniskan, H. Ü., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay5154 · Cited by 292
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
Remillard, D., Buckley, D. L., Paulk, J., Brien, G. L., Sonnett, M., Seo, H., Dastjerdi, S., Wühr, M., Dhe‐Paganon, S., Armstrong, S. A., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611281 · Cited by 288
Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity
Pao, K.-C., Wood, N. T., Knebel, A., Rafie, K., Stanley, M., Mabbitt, P. D., Sundaramoorthy, R., Hofmann, K., van Aalten, D. M. F., & Virdee, S. (2018) · Nature · doi:10.1038/s41586-018-0026-1 · Cited by 288
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Brand, M., Jiang, B., Bauer, S., Donovan, K. A., Liang, Y., Wang, E. S., Nowak, R. P., Yuan, J. C., Zhang, T., Kwiatkowski, N., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.006 · Cited by 258
The MAGE protein family and cancer
Weon, J. L., & Potts, P. R. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.08.002 · Cited by 257
Self-citationPROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Khan, S., He, Y., Zhang, X., Yuan, Y., Pu, S., Kong, Q., Zheng, G., & Zhou, D. (2020) · Oncogene · doi:10.1038/s41388-020-1336-y · Cited by 252
Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
Imaide, S., Riching, K. M., Makukhin, N., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N., Mahan, S. D., Murphy, N., Cowan, A. D., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00878-4 · Cited by 251
Regulation of WASH-Dependent Actin Polymerization and Protein Trafficking by Ubiquitination
Hao, Y.-H., Doyle, J. M., Ramanathan, S., Gomez, T. S., Jia, D., Xu, M., Chen, Z. J., Billadeau, D. D., Rosen, M. K., & Potts, P. R. (2013) · Cell · doi:10.1016/j.cell.2013.01.051 · Cited by 246
Self-citationHughes, S. J., & Ciulli, A. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170041 · Cited by 240
Pike, A., Williamson, B., Harlfinger, S., Martin, S., & McGinnity, D. F. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.013 · Cited by 232
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
Mares, A., Miah, A. H., Smith, I. E. D., Rackham, M., Thawani, A. R., Cryan, J., Haile, P. A., Votta, B. J., Beal, A. M., Capriotti, C., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0868-6 · Cited by 232
PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes
Zaidman, D., Prilusky, J., & London, N. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00589 · Cited by 224
Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications
Henning, N. J., Manford, A. G., Spradlin, J. N., Brittain, S. M., Zhang, E., McKenna, J. M., Tallarico, J. A., Schirle, M., Rape, M., & Nomura, D. K. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03980 · Cited by 221
New molecular switch architectures
Harris, J. D., Moran, M. J., & Aprahamian, I. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714499115 · Cited by 220
PROTAC-DB: an online database of PROTACs
Weng, G., Shen, C., Cao, D., Gao, J., Dong, X., He, Q., Yang, B., Li, D., Wu, J., & Hou, T. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa807 · Cited by 219
Optical Control of Small Molecule-Induced Protein Degradation
Naro, Y., Darrah, K., & Deiters, A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12718 · Cited by 218
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Pillow, T. H., Adhikari, P., Blake, R. A., Chen, J., Del Rosario, G., Deshmukh, G., Figueroa, I., Gascoigne, K. E., Kamath, A. V., Kaufman, S., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900497 · Cited by 216
Chan, K.-H., Zengerle, M., Testa, A., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01912 · Cited by 215
Efficient targeted degradation via reversible and irreversible covalent PROTACs
Gabizon, R., Shraga, A., Gehrtz, P., Livnah, E., Gurwicz, N., Avram, L., Unger, T., Albeck, S., Shulman, Z., & London, N. (2020) · doi:10.26434/chemrxiv.11494398.v1 · Cited by 213
Guo, W.-H., Qi, X., Yu, X., Liu, Y., Chung, C.-I., Bai, F., Lin, X., Lu, D., Wang, L., Chen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17997-6 · Cited by 209
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex
Hsu, J. H.-R., Rasmusson, T., Robinson, J., Pachl, F., Read, J., Kawatkar, S., O’ Donovan, D. H., Bagal, S., Code, E., Rawlins, P., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.004 · Cited by 202
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras
Zhang, X., Luukkonen, L. M., Eissler, C. L., Crowley, V. M., Yamashita, Y., Schafroth, M. A., Kikuchi, S., Weinstein, D. S., Symons, K. T., Nordin, B. E., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00990 · Cited by 199
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2622 · Cited by 199
In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
Drummond, M. L., & Williams, C. I. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00872 · Cited by 199
PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
Tinworth, C. P., Lithgow, H., Dittus, L., Bassi, Z. I., Hughes, S. E., Muelbaier, M., Dai, H., Smith, I. E. D., Kerr, W. J., Burley, G. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01094 · Cited by 195
Yang, J., Li, Y., Aguilar, A., Liu, Z., Yang, C.-Y., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00846 · Cited by 190
A complex task? Direct modulation of transcription factors with small molecules
Koehler, A. N. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.022 · Cited by 189
Bolden, J. E., Tasdemir, N., Dow, L. E., van Es, J. H., Wilkinson, J. E., Zhao, Z., Clevers, H., & Lowe, S. W. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.025 · Cited by 185
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
Wu, T., Yoon, H., Xiong, Y., Dixon-Clarke, S. E., Nowak, R. P., & Fischer, E. S. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0438-0 · Cited by 180
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown
Jin, Y.-H., Lu, M.-C., Wang, Y., Shan, W.-X., Wang, X.-Y., You, Q.-D., & Jiang, Z.-Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02058 · Cited by 178
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Potjewyd, F., Turner, A.-M. W., Beri, J., Rectenwald, J. M., Norris-Drouin, J. L., Cholensky, S. H., Margolis, D. M., Pearce, K. H., Herring, L. E., & James, L. I. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.006 · Cited by 175
Dragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Chen, J., Corr, N., dela Cruz-Chuh, J., Del Rosario, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01846 · Cited by 174
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
Wang, L., Shao, X., Zhong, T., Wu, Y., Xu, A., Sun, X., Gao, H., Liu, Y., Lan, T., Tong, Y., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00742-5 · Cited by 168
Balaštík, M., Ferraguti, F., Pires‐daSilva, A., Lee, T. H., Álvarez-Bolado, G., Lu, K. P., & Gruß, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802261105 · Cited by 166
Drummond, M. L., Henry, A., Li, H., & Williams, C. I. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00897 · Cited by 166
The SCF-Fbxo40 Complex Induces IRS1 Ubiquitination in Skeletal Muscle, Limiting IGF1 Signaling
Shi, J., Luo, L., Eash, J. K., Ibebunjo, C., & Glass, D. J. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.09.011 · Cited by 165
Fundamental aspects of DMPK optimization of targeted protein degraders
Cantrill, C., Chaturvedi, P., Rynn, C., Petrig Schaffland, J., Walter, I., & Wittwer, M. B. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.012 · Cited by 162
Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges
Zou, H., Banerjee, P., Leung, S. S. Y., & Yan, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00997 · Cited by 161
Targeting the Small GTPase Superfamily through Their Regulatory Proteins
Gray, J. L., von Delft, F., & Brennan, P. E. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201900585 · Cited by 160
Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
Bai, N., Miller, S. A., Andrianov, G. V., Yates, M., Kirubakaran, P., & Karanicolas, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01451 · Cited by 157
Bardoxolone conjugation enables targeted protein degradation of BRD4
Tong, B., Luo, M., Xie, Y., Spradlin, J. N., Tallarico, J. A., McKenna, J. M., Schirle, M., Maimone, T. J., & Nomura, D. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72491-9 · Cited by 154
MuRF1/TRIM63, Master Regulator of Muscle Mass
Peris-Moreno, D., Taillandier, D., & Polge, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186663 · Cited by 153
Proteome Turnover in the Spotlight: Approaches, Applications, and Perspectives
Ross, A. B., Langer, J. D., & Jovanovic, M. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002190 · Cited by 152
Steinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc00167h · Cited by 148
Chen, S. N., Czernuszewicz, G., Tan, Y., Lombardi, R., Jin, J., Willerson, J. T., & Marian, A. J. (2012) · Circulation Research · doi:10.1161/circresaha.112.270207 · Cited by 147
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Kiely-Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 147
Composition and Regulation of the Cellular Repertoire of SCF Ubiquitin Ligases
Reitsma, J. M., Liu, X., Reichermeier, K. M., Moradian, A., Sweredoski, M. J., Hess, S., & Deshaies, R. J. (2017) · Cell · doi:10.1016/j.cell.2017.10.016 · Cited by 142
Tovell, H., Testa, A., Maniaci, C., Zhou, H., Prescott, A. R., Macartney, T., Ciulli, A., & Alessi, D. R. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01016 · Cited by 141
Scanlan, M. J., Altorki, N. K., Gure, A. O., Williamson, B., Jungbluth, A. A., Chen., Y., & Old, L. J. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00385-7 · Cited by 140
A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases
Lee, A. K., & Potts, P. R. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.005 · Cited by 136
Self-citationA caged E3 ligase ligand for PROTAC-mediated protein degradation with light
Kounde, C. S., Shchepinova, M. M., Saunders, C. N., Muelbaier, M., Rackham, M. D., Harling, J. D., & Tate, E. W. (2020) · Chemical Communications · doi:10.1039/d0cc00523a · Cited by 129
Targeted protein degradation and the enzymology of degraders
Fisher, S. L., & Phillips, A. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.004 · Cited by 126
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Zhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112186 · Cited by 123
Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
Ohoka, N., Tsuji, G., Shoda, T., Fujisato, T., Kurihara, M., Demizu, Y., & Naito, M. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00704 · Cited by 123
A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
Tong, B., Spradlin, J. N., Novaes, L. F. T., Zhang, E., Hu, X., Moeller, M., Brittain, S. M., McGregor, L. M., McKenna, J. M., Tallarico, J. A., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00348 · Cited by 118
Sasaki, A., Masuda, Y. M., Iwaï, K., Ikeda, K., & Watanabe, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109728200 · Cited by 116
Cereblon modulators: Low molecular weight inducers of protein degradation
Chamberlain, P. P., & Cathers, B. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.004 · Cited by 106
Protein degradation through covalent inhibitor-based PROTACs
Xue, G., Chen, J., Liu, L., Zhou, D., Zuo, Y., Fu, T., & Pan, Z. (2020) · Chemical Communications · doi:10.1039/c9cc08238g · Cited by 104
The E3 Ubiquitin Ligase TRIM9 Is a Filopodia Off Switch Required for Netrin-Dependent Axon Guidance
Menon, S., Boyer, N. P., Winkle, C. C., McClain, L. M., Hanlin, C. C., Pandey, D. B., Rothenfußer, S., Taylor, A. M., & Gupton, S. L. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.11.022 · Cited by 103
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
Kostic, M., & Jones, L. H. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.006 · Cited by 91
MAGE cancer-testis antigens protect the mammalian germline under environmental stress
Tacer, K. F., Montoya, M. C., Oatley, M. J., Lord, T., Oatley, J. M., Klein, J. D., Ravichandran, R., Sheppard, H., Kim, M., Connelly, J. P., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4832 · Cited by 87
Self-citationZhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications · doi:10.1039/c9cc07217a · Cited by 86
Chemo-proteomics exploration of HDAC degradability by small molecule degraders
Xiong, Y., Donovan, K. A., Eleuteri, N. A., Kirmani, N., Yue, H., Razov, A., Krupnick, N. M., Nowak, R. P., & Fischer, E. S. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.07.002 · Cited by 86
The Melanoma Antigen Genes—Any Clues to Their Functions in Normal Tissues?
Forslund, K. Ö., & Nordqvist, K. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5173 · Cited by 83
Ubiquitin ligase RNF167 regulates AMPA receptor-mediated synaptic transmission
Lussier, M. P., Herring, B. E., Nasu-Nishimura, Y., Neutzner, A., Karbowski, M., Youle, R. J., Nicoll, R. A., & Roche, K. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217477109 · Cited by 78
PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
Reichermeier, K. M., Straube, R., Reitsma, J. M., Sweredoski, M. J., Rose, C. M., Moradian, A., den Besten, W., Hinkle, T., Verschueren, E., Petzold, G., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.013 · Cited by 78
The rise and rise of protein degradation: Opportunities and challenges ahead
Hughes, S. J., Testa, A., Thompson, N., & Churcher, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.006 · Cited by 76
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
Zhang, X., He, Y., Zhang, P., Budamagunta, V., Lv, D., Thummuri, D., Yang, Y., Pei, J., Yuan, Y., Zhou, D., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112397 · Cited by 71
Specific MHC-I Peptides Are Induced Using PROTACs
Jensen, S. M., Potts, G. K., Ready, D. B., & Patterson, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02697 · Cited by 68
TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotection upon Ischemic Stroke in Mice
Zeng, J., Wang, Y., Luo, Z., Chang, L.-C., Yoo, J. S., Yan, H., Choi, Y., Xie, X., Deverman, B. E., Gradinaru, V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.055 · Cited by 64
The E3‐ubiquitin ligase TRIM2 regulates neuronal polarization
Khazaei, M. R., Bunk, E. C., Hillje, A., Jahn, H. M., Riegler, E. M., Knoblich, J. A., Young, P., & Schwamborn, J. C. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06971.x · Cited by 58
Tomoshige, S., Hashimoto, Y., & Ishikawa, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.035 · Cited by 54
Ye, J., Zhang, Y., Xu, J., Zhang, Q., & Zhu, D. (2007) · Gene · doi:10.1016/j.gene.2007.08.020 · Cited by 52
Targeting transcription factors for therapeutic benefit
Brennan, P., Donev, R., & Hewamana, S. (2008) · Molecular BioSystems · doi:10.1039/b801920g · Cited by 52
Covalent PROTACs: the best of both worlds?
Grimster, N. P. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00191d · Cited by 52
Evolutionary History of the Cancer Immunity Antigen MAGE Gene Family
Katsura, Y., & Satta, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020365 · Cited by 51
Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy
Salazar-Mendiguchía, J., Ochoa, J. P., Palomino-Doza, J., Domínguez, F., Díez-López, C., Akhtar, M., Ramiro-León, S., Clemente, M. M., Pérez-Cejas, A., Robledo, M., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-316913 · Cited by 47
Kozakova, L., Vondrova, L., Stejskal, K., Charalabous, P., Kolesar, P., Lehmann, A. R., Uldrijan, S., Sanderson, C. M., Zdrahal, Z., & Palecek, J. J. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1000112 · Cited by 46
López‐Sánchez, N., González-Fernández, Z., Niinobe, M., Yoshikawa, K., & Frade, J. M. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00249.2006 · Cited by 44
Photocrosslinking Activity-Based Probes for Ubiquitin RING E3 Ligases
Mathur, S., Fletcher, A. J., Branigan, E., Hay, R. T., & Virdee, S. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.013 · Cited by 43
Yang, S. W., Huang, X., Lin, W., Min, J., Miller, D. J., Mayasundari, A., Rodrigues, P., Griffith, E. C., Gee, C. T., Li, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18708-x · Cited by 41
Self-citationDeficiency in Kelch protein Klhl31 causes congenital myopathy in mice
Papizan, J. B., Garry, G. A., Brezprozvannaya, S., McAnally, J., Bassel‐Duby, R., Liu, N., & Olson, E. N. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93445 · Cited by 40
Controlling PROTACs with Light
Verma, S., & Manna, D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000249 · Cited by 39
Moser, S. C., Voerman, J. S. A., Buckley, D. L., Winter, G. E., & Schliehe, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01920 · Cited by 35
Differential Evolution of MAGE Genes Based on Expression Pattern and Selection Pressure
Zhao, Q., Caballero, O. L., Simpson, A. J. G., & Strausberg, R. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048240 · Cited by 29
Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
Zeng, S., Zhang, H., Shen, Z., & Huang, W. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.639176 · Cited by 28
The Vital Role of Proteomics in Characterizing Novel Protein Degraders
Zhang, A. X., Cassidy, K. B., Dahl, G., Moreau, K., Pachl, F., & Zuhl, A. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220985776 · Cited by 23
Massafra, V., Tundo, S., Dietzig, A., Ducret, A., Jöst, C., Klein, C., Kontermann, R. E., Knoetgen, H., Steegmaier, M., Romagnani, A., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000252 · Cited by 23
Yu, W., Li, Y., Zhou, X., Deng, Y., Wang, Z., Yuan, W., Li, D., Zhu, C., Zhao, X., Mo, X., et al. (2008) · Molecules and Cells · doi:10.1016/s1016-8478(23)14020-9 · Cited by 20
Fbxo41 Promotes Disassembly of Neuronal Primary Cilia
King, C. R., Quadros, A. R. A. D. A., Chazeau, A., Saarloos, I., van der Graaf, A. J., Verhage, M., & Toonen, R. F. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-44589-2 · Cited by 17
Mukherjee, C., Holubowska, A., Schwedhelm‐Domeyer, N., Mitkovski, M., Lee, S., Kannan, M., Matz, A., Vadhvani, M., & Stegmüller, J. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2133-14.2015 · Cited by 16
Electrophilic Screening Platforms for Identifying Novel Covalent Ligands for E3 Ligases
Zheng, S., & Crews, C. M. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00301 · Cited by 8
Research works printed but not linked: 1
- Chomez, 2001, Cancer Res., 61, 5544
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
Li, X., Chen, M., Chen, X., He, X., Li, X., Wei, H., Tan, Y., Min, J., Azam, T., Xue, M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae379 · Cited by 198
Self-citationNew-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Wang, C., Zhang, Y., Chen, W., Wu, Y., & Xing, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02024-9 · Cited by 188
Metadata
- Authors
- Guenette, R. G., Yang, S. W., Min, J., Pei, B., & Potts, P. R.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Potts, Patrick Ryan
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2022
- Volume
- 51
- Issue
- 14
- Pages
- 5740-5756
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W4280616471
- Cited by
- 324
- References
- 133
- Citations by year
- 2026: 87 · 2025: 110 · 2024: 77 · 2023: 40 · 2022: 10
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- PROTACs, targeted protein degradation, tissue selectivity, E3 ubiquitin ligase, bifunctional molecules, linker optimization, undruggable proteins, small molecule drug discovery
- MeSH terms
- Ligands, Ubiquitin-Protein Ligases, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.